Skip to main content

“The Nail in the Coffin for Fibrates”: Futility of PROMINENT Trial Definitively Settles Debate on Avoiding Use of Fibrate Class of Medications for Cardiovascular Risk Reduction

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
“The Nail in the Coffin for Fibrates”: Futility of PROMINENT Trial Definitively Settles Debate on Avoiding Use of Fibrate Class of Medications for Cardiovascular Risk Reduction

User login

Username

Password

Reset your password

Type	Lead	score